LCZ696 与心力衰竭患者肾功能的保护：6 项随机试验的荟萃分析。
LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials.
机构信息
Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Key Lab of Cardiovascular Disease of Zhejiang Province, Hangzhou, Zhejiang 310009, P. R. China.
出版信息
Rev Cardiovasc Med. 2020 Mar 30;21(1):113-118. doi: 10.31083/j.rcm.2020.01.2.
Patients with heart failure (HF) are prone to combine with renal insufficiency. Recently, LCZ696 has been used in the treatment of HF, but whether LCZ696 is better than angiotensin converting enzyme inhibitors/angiotensin receptor antagonists (ACEI/ARB) in renal protection for HF patients has not been investigated. Therefore, we conducted a meta-analysis focusing on LCZ696 and its role in preservation of renal function in HF patients. Embase, PubMed, the Cochrane Library and ClinicalTrials.gov databases were electronically searched for available randomized controlled trials (RCTs). HF patients taking LCZ696 or ACEI/ARB were assessed for renal adverse events. The last search date was Sep 20, 2019. A total of 14959 patients from 6 trials were included in this meta-analysis. As compared to ACEI/ARB, LCZ696 significantly reduced the risk of renal function deterioration (odds ratio 0.77, 95% confidence interval 0.61-0.97, = 0.02). In summary, LCZ696 may have superior renal protection in HF patients compared with ACEI/ARB.
心力衰竭（HF）患者易合并肾功能不全。最近，LCZ696 已被用于 HF 的治疗，但 LCZ696 在 HF 患者的肾脏保护方面是否优于血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂（ACEI/ARB）尚未得到研究。因此，我们进行了一项荟萃分析，重点关注 LCZ696 及其在 HF 患者肾功能保护中的作用。电子检索了 Embase、PubMed、Cochrane 图书馆和 ClinicalTrials.gov 数据库中可用的随机对照试验（RCT）。评估了服用 LCZ696 或 ACEI/ARB 的 HF 患者的肾脏不良事件。最后一次检索日期为 2019 年 9 月 20 日。共有 6 项试验的 14959 名患者纳入了这项荟萃分析。与 ACEI/ARB 相比，LCZ696 可显著降低肾功能恶化的风险（比值比 0.77，95%置信区间 0.61-0.97， = 0.02）。总之，LCZ696 可能比 ACEI/ARB 对 HF 患者具有更好的肾脏保护作用。
Zotero 插件